- Home
- BAK vs IOVA Comparison
BAK vs IOVA Comparison
Compare BAK & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAK
- IOVA
- Stock Information
- Founded
- BAK 1972
- IOVA 2007
- Country
- BAK Brazil
- IOVA United States
- Employees
- BAK N/A
- IOVA N/A
- Industry
- BAK Major Chemicals
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BAK Industrials
- IOVA Health Care
- Exchange
- BAK Nasdaq
- IOVA Nasdaq
- Market Cap
- BAK 1.0B
- IOVA 975.1M
- IPO Year
- BAK N/A
- IOVA N/A
- Fundamental
- Price
- BAK $2.53
- IOVA $2.22
- Analyst Decision
- BAK Hold
- IOVA Buy
- Analyst Count
- BAK 2
- IOVA 11
- Target Price
- BAK $4.40
- IOVA $11.90
- AVG Volume (30 Days)
- BAK 1.4M
- IOVA 10.0M
- Earning Date
- BAK 11-05-2025
- IOVA 11-06-2025
- Dividend Yield
- BAK N/A
- IOVA N/A
- EPS Growth
- BAK N/A
- IOVA N/A
- EPS
- BAK N/A
- IOVA N/A
- Revenue
- BAK $14,266,076,929.00
- IOVA $241,525,000.00
- Revenue This Year
- BAK $3.02
- IOVA $68.14
- Revenue Next Year
- BAK $10.17
- IOVA $56.64
- P/E Ratio
- BAK N/A
- IOVA N/A
- Revenue Growth
- BAK 10.48
- IOVA 636.99
- 52 Week Low
- BAK $2.42
- IOVA $1.64
- 52 Week High
- BAK $7.34
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- BAK 35.59
- IOVA 48.90
- Support Level
- BAK $2.44
- IOVA $2.09
- Resistance Level
- BAK $2.59
- IOVA $2.34
- Average True Range (ATR)
- BAK 0.13
- IOVA 0.12
- MACD
- BAK -0.03
- IOVA 0.02
- Stochastic Oscillator
- BAK 12.42
- IOVA 62.20
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.